Hsp70 Trap Assay for Detection of Misfolded Subproteome Related to Myelodysplastic Syndromes

0518388 - ÚFE 2020 RIV US eng J - Článek v odborném periodiku
Pastva, O. - Chrastinová, L. - Bocková, Markéta - Kotlín, R. - Suttnar, J. - Hlaváčková, A. - Štikarová, J. - Ceznerová, E. - Čermák, J. - Homola, Jiří - Dyr, J. E.
Hsp70 Trap Assay for Detection of Misfolded Subproteome Related to Myelodysplastic Syndromes.
Analytical Chemistry. Roč. 91, č. 22 (2019), s. 14226-14230. ISSN 0003-2700. E-ISSN 1520-6882
Grant CEP: GA ČR(CZ) GBP205/12/G118; GA ČR(CZ) GA19-02739S
Institucionální podpora: RVO:67985882
Klíčová slova: Diagnosis * Proteins
Obor OECD: Analytical chemistry
Impakt faktor: 6.785, rok: 2019
Způsob publikování: Omezený přístup
https://pubs.acs.org/doi/10.1021/acs.analchem.9b04175

The onset and progression of numerous serious diseases (e.g., various types of malignancies, neuro-degenerative diseases, and cardiac diseases) are, on a molecular level, associated with protein modifications and misfolding. Current methods for the detection of misfolded proteins are not able to detect the whole misfolded subproteome and, moreover, are rather laborious and time consuming. Herein, we report on a novel simple method for the detection of misfolded proteins employing a surface plasmon resonance (SPR) biosensor and heat shock protein 70 (Hsp70) that recognizes and traps misfolded proteins in a nucleotide-dependent manner. We use this method for the detection of misfolded proteins in blood plasma of patients with various subtypes of myelodysplastic syndromes (MDS) and healthy donors. Our results reveal significantly elevated levels of misfolded proteins in the two stages of MDS that are most affected by oxidative stress: low-risk (RARS) and intermediate-risk (RCMD) patients. This approach can be extended to a variety of diseases and provides unique insights into the thus far unexplored area of blood proteome.
Trvalý link: http://hdl.handle.net/11104/0303537